Movatterモバイル変換


[0]ホーム

URL:


Skip to main content
NCBI home page
Search in PMCSearch
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more:PMC Disclaimer | PMC Copyright Notice
Clinical Medicine logo

Helicobacter pylori: 20 years on

Barry Marshall1
1Helicobacter pylori Research Laboratory, Queen Elizabeth II Medical Centre, Nedlands, Western Australia

Roles

Barry Marshall:FRACP FAA FRS,NHMRC Research Fellow
© 2002 Royal College of Physicians
PMCID: PMC4952378  PMID:11991099

Abstract

Helicobacters are a new genus of bacteria, inhabiting the interface between mucosa and lumen of the gut. Microaerophilic, spiral, flagellated and urease positive, they possess features necessary for colonisation of the juxtamucosal mucus environment.Helicobacter pylori is the major pathogenic species. Once attached to the gastric epithelial cells, it incites an immune response characterised histologically by the development of active gastritis and immunologically by the presence of specific IgG. Persistence of infection is ensured by attachment to tissue antigens (eg Lewis B), a vacuolating toxin (VacA) which assists the free passage of urea through epithelial cells, and a cytotoxin (CagA) which is actually injected into the epithelial cells via a Type IV secretion system. Finally, during the typical lifelong chronic infection, two important diseases occur.H. pylori alters gastric physiology to cause acid hypersecretion and peptic ulcer. Secondly, it damages the acid secreting mucosa leading to atrophic gastritis and gastric cancer risk.

Keywords: cagA, gastritis, helicobacter, peptic ulcer, stomach cancer, toxin, Ulcer, urease, VacA

Full Text

The Full Text of this article is available as aPDF (232.3 KB).


Articles from Clinical Medicine are provided here courtesy ofRoyal College of Physicians

ACTIONS

RESOURCES


[8]ページ先頭

©2009-2025 Movatter.jp